World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
83
Citations
34967
World Ranking
15400
National Ranking
11

Overview

Roman Hájek is affiliated with the University of Ostrava in the Czech Republic and has a research portfolio spanning medicine and biochemistry, genetics, and molecular biology. Their work prominently addresses hematology, molecular biology, oncology, genetics, and immunology.

Among the notable recent papers featuring Roman Hájek's research are:

  • Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia, 2020, New England Journal of Medicine
  • Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, 2021, Annals of Oncology
  • Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma, 2023, New England Journal of Medicine
  • Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study, 2020, The Lancet Haematology
  • Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial, 2021, The Lancet

Roman Hájek has frequently collaborated with researchers including:

  • Meletios Α. Dimopoulos
  • Tomáš Jelı́nek
  • Philippe Moreau
  • Ivan Špıčka
  • Pieter Sonneveld

The primary publication venues for their work include:

  • Blood
  • Clinical Lymphoma Myeloma & Leukemia
  • Journal of Clinical Oncology
  • HemaSphere
  • Blood Cancer Journal

The main scientific fields they contribute to are:

  • Medicine
  • Biochemistry, Genetics and Molecular Biology

Subfields of specific focus include:

  • Hematology
  • Molecular Biology
  • Oncology
  • Genetics
  • Immunology

Key research topics covered in their publications are:

  • Multiple Myeloma Research and Treatments
  • Protein Degradation and Inhibitors
  • Peptidase Inhibition and Analysis
  • Cancer Treatment and Pharmacology
  • Chronic Lymphocytic Leukemia Research
  • CAR-T cell therapy research
  • Myeloproliferative Neoplasms: Diagnosis and Treatment

Best Publications

  • Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia

    Courtney D DiNardo;Brian A Jonas;Vinod Pullarkat;Michael J Thirman

  • Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study

    Meletios Athanasios Dimopoulos;Philippe Moreau;Antonio Palumbo;Douglas Edgar Joshua

  • International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders

    A. Dispenzieri;R. Kyle;G. Merlini;J. S. Miguel

  • Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management

    R A Kyle;B G M Durie;S V Rajkumar;O Landgren

  • Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma

    Antonio Palumbo;Roman Hajek;Michel Delforge;Martin Kropff

  • Randomized Phase III Study of Pegylated Liposomal Doxorubicin Plus Bortezomib Compared With Bortezomib Alone in Relapsed or Refractory Multiple Myeloma: Combination Therapy Improves Time to Progression

    Robert Z. Orlowski;Arnon Nagler;Pieter Sonneveld;Joan Bladé

  • Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

    P. Moreau;J. San Miguel;P. Sonneveld;M. V. Mateos

  • Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report

    Antonio Palumbo;Sara Bringhen;Maria Victoria Mateos;Alessandra Larocca

  • Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study

    Michel Attal;Paul G. Richardson;S. Vincent Rajkumar;Jesus San-Miguel

  • Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

    Steven Horwitz;Owen A O'Connor;Barbara Pro;Tim Illidge

  • TGF-β – an excellent servant but a bad master

    Lenka Kubiczkova;Lenka Sedlarikova;Roman Hajek;Sabina Sevcikova

  • Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†.

    M A Dimopoulos;P Moreau;E Terpos;M V Mateos

  • International Myeloma Working Group Consensus Statement for the Management, Treatment, and Supportive Care of Patients With Myeloma Not Eligible for Standard Autologous Stem-Cell Transplantation

    Antonio Palumbo;S. Vincent Rajkumar;Jesus F. San Miguel;Alessandra Larocca

  • Personalized therapy in multiple myeloma according to patient age and vulnerability: A report of the European Myeloma Network (EMN)

    Antonio Palumbo;Sara Bringhen;Heinz Ludwig;Meletios A. Dimopoulos

  • Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group

    C. Fernández De Larrea;R. A. Kyle;B. G.M. Durie;H. Ludwig

  • Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2

    Nikhil Munshi;Nikhil Munshi;Kenneth Carl Anderson;Leif Bergsagel;John Shaughnessy

  • Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial

    Meletios A. Dimopoulos;Hartmut Goldschmidt;Ruben Niesvizky;Douglas Joshua

  • European Myeloma Network Guidelines for the Management of Multiple Myeloma-related Complications

    Evangelos Terpos;Martina Kleber;Monika Engelhardt;Sonja Zweegman

  • Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.

    Stefania Oliva;Maria Teresa Petrucci;Concetta Conticello

  • Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study

    Michele Cavo;Meral Beksac;Lucia Pantani

Frequent Co-Authors

Meletios A. Dimopoulos
Meletios A. Dimopoulos National and Kapodistrian University of Athens
Heinz Ludwig
Heinz Ludwig University of Vienna
Pieter Sonneveld
Pieter Sonneveld Erasmus University Rotterdam
Antonio Palumbo
Antonio Palumbo University of Turin
Mario Boccadoro
Mario Boccadoro University of Turin
Andrew Spencer
Andrew Spencer Monash University
Michele Cavo
Michele Cavo University of Bologna
Maria-Victoria Mateos
Maria-Victoria Mateos University of Salamanca
Sonja Zweegman
Sonja Zweegman Amsterdam UMC
Paul G. Richardson
Paul G. Richardson Harvard University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you are interested in a healthcare career but aren't ready to commit to a full medical degree, there are several alternative online pathways to consider. For those looking to get started quickly, online nursing courses can provide foundational skills and certification options.

Registered nurses seeking career advancement can enroll in rn to bsn online programs to boost credentials and open doors to leadership roles. For those aiming for the highest qualifications, pursuing an online phd nursing allows you to focus on research, teaching, or advanced clinical practice, all while offering the flexibility of distance learning.

If you have a non-nursing bachelor's degree but are considering a fast-track route into advanced practice, there are direct entry np programs for non nurses online that provide a pathway to become a nurse practitioner without prior nursing experience. Each of these flexible options supports different career goals and adapts well to varying educational backgrounds.

Best Scientists Citing Roman Hájek

Trending Scientists

Recently Published Articles